In Q4 2017, HS Pharmaceuticals will be initiating a new collaborative cancer research effort between The Medical University of South Carolina in Charleston, South Carolina and LifeArc (formerly The Medical Research Council) at Cambridge University in Cambridge, England.
HS Pharmaceuticals has licensed technology from LifeArc that is focused on the silica nanoclusters application to T-cell activation for oncology research and development.
Currently, the company is coordinating four cancer research pilot projects identified by Jonathan Powell, PhD, Cambridge University and Dr Zihai Li, Chairman and Professor in Department of Microbiology & Immunology at MUSC.
Dr. Powell has recently submitted his research, which is the basis of these pilot programs, for peer-reviewed publication.
These pilot research programs, using animal and human cells, hope to show promising direction for oncological immunotherapy applications.
The four identified pilot projects will:
- Project 1 – Determine whether nanoparticles can program naïve murine CD4 T cells to Tregs and other lineages.
- Project 2 – Investigate SNC effects in vivo using CD8 and CD4 T cell and in vivo using the CAR/TIL model.
- Project 3 – Immune characterization of cell surface molecules blocked by silica nanoclusters by performing flow cytometry on mouse and human lymphocytes.
- Project 4 – Determine whether MYXV particles coated with SNCs prevent liver absorption after intertumoral injection.